Liminatus Pharma, Inc. (LIMN) Key Metrics
LIMN valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $4.1M
- Enterprise value
- $3.8M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 18.0
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.75
LIMN key metrics, 2021–2025
Fiscal year ended December 31, 2025 · U.S. dollarsLIMN valuation Price multiples at each fiscal year-end price.
LIMN returns How much profit the business earns on the capital it uses.
LIMN per-share figures Results divided by the shares outstanding at year-end.
LIMN financial health Debt, liquidity and how easily interest is covered.
LIMN valuation history
LIMN returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
LIMN debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
LIMN cash returned to shareholders
LIMN price vs earnings per share
LIMN key metrics
2021–2025| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Valuation | |||||
| Market capitalization | $14.5M | — | — | $348.4M | $337.4M |
| Enterprise value | $15.6M | — | — | $359.9M | $337.2M |
| P/E ratio | — | — | — | — | 77.2 |
| Price / book | — | — | — | 269.2 | 1.3 |
| EV / EBITDA | — | — | — | — | 77.2 |
| Earnings yield | −70.4% | — | — | −0.8% | 1.3% |
| Free cash flow yield | −68.9% | — | — | −0.2% | −0.4% |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.2% | — |
| Share price at fiscal year-end | $30.50 | $561.00 | $516.50 | $506.00 | $489.00 |
| Per share | |||||
| Revenue per share | $0.00 | — | — | $0.00 | $0.00 |
| Earnings per share | −$21.48 | — | — | −$4.25 | $6.33 |
| Operating cash flow per share | −$20.97 | — | — | −$1.26 | −$1.76 |
| Free cash flow per share | −$21.00 | — | — | −$1.26 | −$1.76 |
| Cash per share | $0.71 | — | — | $7.33 | $0.49 |
| Book value per share | −$20.66 | — | — | $1.88 | $369.38 |
| Tangible book value per share | −$20.66 | — | — | $1.88 | $369.38 |
| Capex per share | $0.03 | — | — | $0.00 | $0.00 |
| Debt per share | $3.04 | — | — | $23.96 | $0.13 |
| Shares outstanding | 475K | — | — | 689K | 690K |
| Change in shares outstanding | — | — | — | −0.2% | — |
| Returns & profitability | |||||
| Return on equity (ROE) | — | — | — | −2.3% | 1.7% |
| Return on invested capital (ROIC) | — | — | −23.1% | −1.6% | −0.8% |
| Return on assets (ROA) | −610.9% | −79.2% | −12.3% | −2.0% | 1.6% |
| Return on tangible assets | — | −102.7% | −27.2% | −18.9% | 1.6% |
| Income quality (OCF / net income) | — | — | — | — | −0.28 |
| Financial health | |||||
| Total debt | $1.4M | $5.1M | $16.1M | $16.5M | $90,000 |
| Cash & short-term investments | $337,655 | $804,538 | $434,000 | $5.0M | $336,228 |
| Net debt | $1.1M | $4.3M | $15.6M | $11.5M | −$246,228 |
| Debt / equity | — | — | — | 12.75 | 0.00 |
| Debt / assets | 2.81 | 1.81 | 3.56 | 1.07 | 0.00 |
| Net debt / EBITDA | — | — | — | — | −0.06 |
| Current ratio | 0.05 | 0.09 | 0.04 | 0.10 | 0.31 |
| Quick ratio | 0.05 | 0.09 | 0.04 | 0.10 | 0.31 |
| Interest coverage | -13.7 | -21.0 | -14.8 | -12.4 | — |
| Working capital | −$9.8M | −$7.9M | −$4.9M | −$3.2M | −$958,467 |
| Invested capital | −$8.7M | −$11.6M | $4.9M | $12.7M | $254.6M |
| Tangible asset value | −$9.8M | −$15.9M | −$10.7M | $1.3M | $254.9M |
| Net current asset value | −$9.8M | −$17.9M | −$15.0M | −$13.8M | −$21.1M |
| Graham number | — | — | — | — | $229.42 |
| Graham net-net per share | −$21.03 | — | — | −$13.17 | −$30.77 |
| Capital allocation | |||||
| Share buybacks (net) | — | $1.8M | $10.7M | $700,000 | — |
| Capex / depreciation | 7.17 | — | — | 0.00 | — |
| Efficiency | |||||
| Receivables turnover | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | — | $475,728 | $522,500 | $50,628 | $1,256 |
| Average payables | $1.0M | $1.2M | $720,500 | $463,500 | $419,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from LIMN's annual financial statements (latest annual report filed March 31, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
LIMN valuation and financial ratios
It ended the year with $1.4 million of debt and $0.3 million in cash and short-term investments, net debt of $1.1 million. The share count fell 31.1% from 690K to 475K over 4 years.
See the LIMN income statement, the LIMN chart for price history, or the LIMN stock overview for the latest quote and news.
LIMN key metrics FAQ
How much debt does Liminatus Pharma have?
Liminatus Pharma had total debt of $1.4 million at the end of fiscal 2025.
What is Liminatus Pharma's free cash flow yield?
Liminatus Pharma generated -$10.0 million of free cash flow in fiscal 2025, a free cash flow yield of −68.9% on its market value at year-end ($14.5 million).
What is Liminatus Pharma's current ratio?
Liminatus Pharma's current ratio was 0.05 at the end of fiscal 2025: current assets were 0.05 times current liabilities.